title: Ischemia: reperfusion syndrome of the lower limbs.
abstract: The ischemia-reperfusion syndrome, first described by Haimovici in 1960, is a severe complication following surgery for acute ischemia. We evaluated the incidence of this complication in 264 patients operated on between 1972 and 1981 (1st group) and compared it with another of 392 patients operated on between 1982 and 1991 (2nd group), our aim being to assess the effects of pharmacological prophyiaxis based on preoperative overhydration followed by an intra-arterial bolus of 250 ml 14/1000 HCO3-, containing 1 g dexamethasone and 2500 I.U. sodium heparin, injected into the femoral artery before suturing the arteriotomy. This regimen was based on the measurement of myoglobin and glutathione levels respectively carried out in two subgroups of 25 patients. The results of experimental ischemia-reperfusion syndromes induced in animal using radical scavengers and membrane-protective compounds were also taken into consideration. Following experimental research on sheep, 5 patients in the second group with very severe ischemia due to aortic occlusion received local dialysis in the extracorporeal circulation using hemodialysis or hemofiltration techniques. Mortality was 6.3% in the first group and 5.4% in the second, while the amputation rate was 3% and 1.8% respectively. The overall incidence of the reperfusion syndrome was 3% in the 1st period and 1.8% in the second. Our findings confirm the protective effect of hyper-hydration, radical scavengers and dexamethasone in the ischemia reperfusion syndrome, and indicate that local hemodialysis is a useful adjunct in very severe ischemia.
authors.affiliation: University of Bologna, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Magnoni
authors.forename: L
authors.initials: L
authors.lastname: Pedrini
authors.forename: N
authors.initials: N
authors.lastname: Palumbo
authors.forename: M R
authors.initials: MR
authors.lastname: Cirelli
authors.forename: G L
authors.initials: GL
authors.lastname: Faggioli
mesh_terms: D000368:Aged; D000818:Animals; D016022:Case-Control Studies; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D005112:Extracorporeal Circulation; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000627:therapeutic use; D005978:Glutathione / Q000097:blood; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006614:Hindlimb / Q000098:blood supply; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D007866:Leg / Q000098:blood supply*; D008875:Middle Aged; D009211:Myoglobin / Q000097:blood; D016491:Peripheral Vascular Diseases / Q000601:surgery; D015427:Reperfusion Injury / Q000453:epidemiology / Q000517:prevention & control; D012756:Sheep; D017693:Sodium Bicarbonate / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016166:Free Radical Scavengers; D009211:Myoglobin; D003907:Dexamethasone; D017693:Sodium Bicarbonate; D006493:Heparin; D005978:Glutathione